Checkpoint Trends Ltd
Incorporated in 1991, Checkpoint Trends Ltd is in the business of trading and consultancy[1]
- Market Cap ₹ 26.9 Cr.
- Current Price ₹ 49.2
- High / Low ₹ 144 / 16.1
- Stock P/E 13.1
- Book Value ₹ 3.60
- Dividend Yield 0.00 %
- ROCE 16.5 %
- ROE 9.17 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
- Stock is trading at 13.7 times its book value
- The company has delivered a poor sales growth of -12.8% over past five years.
- Company has a low return on equity of 0.00% over last 3 years.
- Company has high debtors of 212 days.
- Working capital days have increased from 220 days to 387 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 0 | 0 | 0 | 2 | 1 | 1 | 0 | 2 | 1 | 1 | 0 | 295 | |
| 0 | 0 | 0 | 0 | 2 | 1 | 1 | 0 | 2 | 1 | 1 | 0 | 292 | |
| Operating Profit | -0 | -0 | -0 | 0 | -0 | -0 | 0 | 0 | -0 | -0 | 0 | 0 | 3 |
| OPM % | -5% | 10% | -1% | -31% | 2% | 2% | -1% | -7% | 3% | 20% | 1% | ||
| 0 | -3 | 0 | 0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | -0 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | -0 | -3 | -0 | 0 | -0 | -0 | 0 | 0 | -0 | -0 | 0 | 0 | 3 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 20% | 0% | 50% | 0% | -50% | 40% | |
| -0 | -3 | -0 | 0 | -0 | -0 | 0 | 0 | -0 | -0 | 0 | 0 | 2 | |
| EPS in Rs | -0.11 | -5.61 | -0.02 | 0.05 | -0.29 | -0.02 | 0.05 | 0.02 | -0.07 | -0.15 | 0.05 | 0.05 | 3.72 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -13% |
| 3 Years: | -37% |
| TTM: | 40822% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 38% |
| 3 Years: | 48% |
| TTM: | 810% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 88% |
| 3 Years: | 115% |
| 1 Year: | 81% |
| Return on Equity | |
|---|---|
| 10 Years: | -1% |
| 5 Years: | -1% |
| 3 Years: | 0% |
| Last Year: | 9% |
Balance Sheet
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Reserves | -2 | -5 | -5 | -5 | -5 | -5 | -5 | -5 | -5 | -5 | -5 | -5 | -4 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 139 | |
| Total Liabilities | 4 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 141 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 4 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 141 | |
| Total Assets | 4 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 141 |
Cash Flows
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0 | -0 | -0 | 0 | 0 | -0 | 0 | 1 | -0 | 0 | 0 | 0 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | -0 | |
| 0 | -0 | -0 | 0 | 0 | -0 | -0 | 0 | 0 | 0 | 0 | 0 | |
| Net Cash Flow | 0 | -0 | -0 | 0 | 0 | -0 | -0 | 1 | -0 | 0 | -0 | 0 |
| Free Cash Flow | -0 | -0 | -0 | 0 | 0 | -0 | 0 | 1 | -0 | 0 | -0 | 0 |
| CFO/OP | 83% | 114% | 100% | 133% | -600% | 17% | 650% | 5,200% | 2,450% | -12% | 0% | 190% |
Ratios
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 36 | 24 | 54 | 179 | 107 | 164 | 122 | 135 | 229 | 212 | ||
| Inventory Days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | 36 | 24 | 54 | 179 | 107 | 164 | 122 | 135 | 229 | 212 | ||
| Working Capital Days | 18 | -35 | 36 | 260 | 221 | 60 | 98 | 129 | 145 | 387 | ||
| ROCE % | -2% | -3% | -3% | 7% | 25% | -31% | 3% | 2% | -3% | -13% | 3% | 17% |
Insights
In beta| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Electricity Consumption Cost INR |
|
|||||||||||
| Debtors Turnover Ratio Ratio |
||||||||||||
| Number of Shareholders Count |
||||||||||||
| Percentage of Shares in Dematerialized Form % |
||||||||||||
| Number of Permanent Employees Count |
||||||||||||
Extracted by Screener AI
Documents
Announcements
-
Clarification On Price Movement Of Equity Shares
24 Apr - April 24, 2026: Company said share price movement is market-driven, with no undisclosed announcements.
-
Clarification Sought from Checkpoint Trends Ltd
15 Apr - Exchange has sought clarification from Checkpoint Trends Ltd on April 15, 2026 with reference to significant movement in price, in order to ensure that investors …
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
9 Apr - Regulation 74(5) confirmation certificate filed for quarter ended March 31, 2026.
-
Closure of Trading Window
24 Mar - Trading window closed from April 1, 2026 until 48 hours after audited results for year ending March 31, 2026.
-
Board Meeting Outcome for Outcome Of Board Meeting
18 Mar - Two independent directors resigned; two additional independent directors appointed effective March 18, 2026.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
CTL (Formerly Rubra Medicaments Ltd) was engaged in the manufacture and sale of pharmaceutical formulations based in Hyderabad. The company is currently in the business of trading and providing different kinds of consulting services in India to all categories of clients.